Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder

Abstract In Thailand, resource limitations lead many multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients to use off-label immunosuppressants. This study assesses the efficacy and safety of rituximab (RTX) with a CD19-based reinfusion regimen among Thai MS and NMOSD pa...

Full description

Bibliographic Details
Published in:	Scientific Reports
Main Authors:	Tatchaporn Ongphichetmetha, Jiraporn Jitprapaikulsan, Sasitorn Siritho, Natthapon Rattanathamsakul, Thammachet Detweeratham, Naraporn Prayoonwiwat
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-02-01
Online Access:	https://doi.org/10.1038/s41598-024-53838-y

Similar Items

Rituximab in secondary progressive multiple sclerosis: a meta‐analysis
by: Pasin Intarakhao, et al.
Published: (2024-10-01)

Author Correction: Tumefactive demyelinating lesions: a retrospective cohort study in Thailand
by: Tatchaporn Ongphichetmetha, et al.
Published: (2024-03-01)

Tumefactive demyelinating lesions: a retrospective cohort study in Thailand
by: Tatchaporn Ongphichetmetha, et al.
Published: (2024-01-01)

Cognitive performance in patients with neuromyelitis optica: clinical and imaging characteristics
by: Natnasak Apiraksattayakul, et al.
Published: (2024-08-01)

Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis
by: Jindapa Srikajon, et al.
Published: (2018-08-01)

Insights into neuromyelitis optica spectrum disorder and pregnancy from a single-center study in Thailand
by: Nuttakarn Budtarad, et al.
Published: (2025-02-01)

The efficacy of disease-modifying therapies in patients with clinically isolated syndrome: a systematic review and network meta-analysis
by: Yanisa Chumpangern, et al.
Published: (2026-03-01)

Use of Complementary and Alternative Medicine in Patients With Idiopathic Inflammatory Demyelinating Diseases of the Central Nervous System: A Cross-Sectional Study in Thailand
by: Punchika Kosiyakul, MD, et al.
Published: (2024-01-01)

Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder
by: Michael T G Hayes, et al.
Published: (2024-04-01)

Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence
by: Masoud Etemadifar, et al.
Published: (2017-01-01)

The risk of dementia in multiple sclerosis and neuromyelitis optica spectrum disorder
by: Eun Bin Cho, et al.
Published: (2023-06-01)

Optical coherence tomography in central nervous system demyelinating diseases related optic neuritis
by: Nattapong Mekhasingharak, et al.
Published: (2018-10-01)

Comparison of inebilizumab or rituximab in addition to glucocorticoid therapy for neuromyelitis optica spectrum disorders
by: Chu-Yuan Lou, et al.
Published: (2024-06-01)

Real-world data on the Immunity Response to the COVID-19 Vaccine among Patients with Central Nervous System Immunological Diseases
by: Punchika Kosiyakul, et al.
Published: (2024-02-01)

Comparative Study of Spectrum of Neuromyelitis Optica and Multiple Sclerosis in Indian Population
by: Sonal Patil, et al.
Published: (2019-10-01)

Association of smoking with risk of multiple sclerosis and neuromyelitis optica spectrum disorders
by: Ting-ting YANG, et al.
Published: (2016-09-01)

Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
by: Fulin Gao, et al.
Published: (2019-03-01)

Neuromyelitis optica spectrum disorder: importance and difficulties of differential diagnosis with multiple sclerosis
by: M. V. Davydovskaya
Published: (2021-07-01)

Comparison of ocular changes in multiple sclerosis and neuromyelitis optica spectrum disorder patients
by: Xiaoyue Wang, et al.
Published: (2024-08-01)

Personalized estimates of morphometric similarity in multiple sclerosis and neuromyelitis optica spectrum disorders
by: Jie Sun, et al.
Published: (2023-01-01)

Superficial white matter integrity in neuromyelitis optica spectrum disorder and multiple sclerosis
by: Darko Komnenić, et al.
Published: (2024-01-01)

Neuromyelitis optica spectrum disorder
by: Simon Broadley, et al.
Published: (2017-09-01)

Neuromyelitis optica spectrum disorders
by: Mohammad Ali Sahraian, et al.
Published: (2026-03-01)

Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study
by: Tanguy Dequidt, et al.
Published: (2025-02-01)

Immunotherapy for neuromyelitis optica spectrum disorder: a comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituximab
by: Jing Zhou, et al.
Published: (2025-04-01)

Neuropsychiatric disorders among Ecuadorian patients with multiple sclerosis and neuromyelitis optica spectrum disorder
by: Edgar Patricio Correa-Díaz, et al.
Published: (2025-07-01)

Diagnostic Potential of Two Novel Biomarkers for Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis
by: Ting Xu, et al.
Published: (2023-04-01)

Multiple sclerosis and neuromyelitis optica spectrum disorders: some similarities in two distinct diseases
by: Hiroaki Yokote, et al.
Published: (2016-01-01)

THE IMPORTANCE OF MRI AS DIAGNOSTIC TOOL IN DIFFERENTIATION BETWEEN MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICA SPECTRUM
by: Mahmoud Abouzeid, et al.
Published: (2025-11-01)

Case Series: Dystonia with multiple sclerosis and neuromyelitis optica
by: Helen Hwang, et al.
Published: (2023-12-01)

Pediatric neuromyelitis optica spectrum disorder
by: Aman Mehta
Published: (2024-01-01)

Neuromyelitis optica spectrum disorders in children
by: N. F. Akhmetgaleeva, et al.
Published: (2024-08-01)

Hypersomnia in Neuromyelitis Optica Spectrum Disorders
by: Hasan Can Güdek, et al.
Published: (2024-06-01)

Neuromyelitis optica spectrum disorders: An update
by: Lekha Pandit
Published: (2015-01-01)

Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study
by: Maral Seyed Ahadi, et al.
Published: (2021-07-01)

Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders
by: Xueli Fan, et al.
Published: (2016-01-01)

Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis
by: Shuo Zhao, et al.
Published: (2021-05-01)

Should tocilizumab be the first line treatment for neuromyelitis optica together with rituximab?
by: R. Sawaya, et al.
Published: (2021-10-01)

Spatiotemporal subtypes of brain and spinal cord atrophy in neuromyelitis optica spectrum disorders and multiple sclerosis
by: Zhizheng Zhuo, et al.
Published: (2025-09-01)

Glutamate as a new path in discrimination between neuromyelitis optica spectrum disorder and multiple sclerosis
by: Amany Mahmoud Rabah, et al.
Published: (2023-11-01)